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Abstract
Background: Intermittent preventive treatment in infants (IPTi) with sulphadoxine-pyrimethamine (SP) for the prevention of
malaria has shown promising results in six trials. However, resistance to SP is rising and alternative drug combinations need
to be evaluated to better understand the role of treatment versus prophylactic effects.
Methods: Between March 2004 and March 2008, in an area of western Kenya with year round malaria transmission with high
seasonal intensity and high usage of insecticide-treated nets, we conducted a randomized, double-blind placebo-controlled
trial with SP plus 3 days of artesunate (SP-AS3), 3 days of amodiaquine-artesunate (AQ3-AS3), or 3 days of short-acting
chlorproguanil-dapsone (CD3) administered at routine expanded programme of immunization visits (10 weeks, 14 weeks
and 9 months).
Principal Findings: 1,365 subjects were included in the analysis. The incidence of first or only episode of clinical malaria
during the first year of life (primary endpoint) was 0.98 episodes/person-year in the placebo group, 0.74 in the SP-AS3
group, 0.76 in the AQ3-AS3 group, and 0.82 in the CD3 group. The protective efficacy (PE) and 95% confidence intervals
against the primary endpoint were: 25.7% (6.3, 41.1); 25.9% (6.8, 41.0); and 16.3% (25.2, 33.5) in the SP-AS3, AQ3-AS3, and
CD3 groups, respectively. The PEs for moderate-to-severe anaemia were: 27.5% (26.9, 50.8); 23.1% (211.9, 47.2); and 11.4%
(228.6, 39.0). The duration of the protective effect remained significant for up to 5 to 8 weeks for SP-AS3 and AQ3-AS3.
There was no evidence for a sustained beneficial or rebound effect in the second year of life. All regimens were well
tolerated.
Conclusions: These results support the view that IPTi with long-acting regimens provide protection against clinical malaria
for up to 8 weeks even in the presence of high ITN coverage, and that the prophylactic rather than the treatment effect of
IPTi appears central to its protective efficacy.
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Introduction
It is estimated that approximately 100 million children aged ,5
years in Africa live in areas where malaria transmission occurs;
each year .800,000 die from the direct effects of malaria [1,2].
Acute febrile illnesses, mostly attributable to malaria, are
responsible for 400–900 million hospitalizations per year among
African children [3]. Malaria-related anaemia is widespread [4]
and its burden falls primarily on infants and children ,5 y ears of
age[ 5,6].
In 2001, Schellenberg and colleagues in Tanzania demonstrated
that intermittent preventive treatment in infants (IPTi) with
sulphadoxine-pyrimethamine (SP) administered at routine Ex-
panded Program of Immunization (EPI) visits with iron supple-
mentation from 2–6 months of age reduced the incidence of
clinical malaria and severe anaemia by 59% (95% CI: 41, 72;
p,0.0001) and 50% (95% CI: 8, 73; p=0.023) respectively in the
first year of life [7]. Another study of IPTi conducted
contemporaneously in northern Tanzania also reported significant
reductions in malarial fevers and severe anaemia (65% [95% CI:
42, 77; p,0.001] and 71% [95% CI: 39, 87; p=0.001]
respectively) using 3 presumptive treatment courses of amodia-
quine (AQ) given at 60 day intervals over 6 months starting at 12–
16 weeks of age [8].
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IPTi with SP is promising [7,9–14], the protective efficacy of IPTi
with SP in more recent trials has been more modest than the initial
Tanzania trial, and a recent study reported no protective efficacy
of IPTi with SP [15]. In addition, Plasmodium falciparum resistance
to SP is high in sub-Saharan Africa [16,17], and alternative drugs
for this strategy need to be identified. The mechanism by which
IPTi works is not well understood: it is unknown whether the
intermittent clearance of existing malaria infections (treatment
effect) or the post-treatment prophylactic effect of long-acting
drugs is more important [18]. It remains uncertain for how long
the protective effect of IPTi persists and whether there is any
evidence for a sustained benefit after the immediate effect of the
drugs have waned [19,20]. There is some evidence from a recent
study showing that the prophylactic effect of the study drug used
was central to the mode of action of IPTi [21]. A better
understanding of the mode of action of IPTi is a key factor in
determining potentially suitable alternative drugs.
We conducted a randomized, double-blind placebo-controlled
trial to evaluate the efficacy and safety of IPTi with regimens
containing short and long-acting anti-malarial drugs administered
at routine EPI vaccinations (at 10, 14 weeks and 9 months). This
was a proof of concept study to understand the importance for
IPTi of the treatment versus prophylactic effect. The trial was
conducted in a rural area of western Kenya with year round
malaria transmission with high seasonal intensity, high SP
treatment failure rates [17] and high usage of insecticide-treated
nets (ITNs). This study was one of a series of trials coordinated by
the IPTi Consortium (www.ipti-malaria.org) [22,23]; this study
aimed to evaluate the efficacy of artemisinin-based combination
drugs as alternatives to the use of SP alone for IPTi.
Methods
Study Area
The study took place in Asembo (Rarieda District, Nyanza
Province), western Kenya, where approximately 55,000 persons
live in 76 villages over 178 square kilometres. The characteristics
of the area have been described in detail elsewhere [24,25]. This
area around Lake Victoria once experienced intense perennial
malaria transmission marked by seasonal variation [26]. However,
transmission rates were reduced by 90% during an ITN efficacy
trial (ITN coverage for children ,5 years of age was 83% in 2002)
conducted from 1996 to 2002 [27,28]. The continued provision of
free ITNs to the entire population has helped to maintain the low
Entomological Inoculation Rate (EIR), currently estimated at 7
infective bites per person per year [24,28]. Despite the reduced
transmission, cross-sectional surveys conducted in 1999, 2000 and
2001 reported the prevalence of parasitaemia and severe anaemia
(Haemoglobin [Hb] ,7 g/dL) among children ,5 years of age as
36% and 10%, respectively [28]. The infant mortality rate in the
study area in 2002 was 125/1,000 live births in [24]. EPI coverage
in the study area is relatively low: 55% of children receive all three
doses of the diphtheria-tetanus toxoid-pertussis-hepatitis B-Hae-
mophilus influenza type b vaccine (PENT) and oral polio vaccine
(OPV), 48% receive the measles vaccine and only 38% receive all
the essential vaccines in the programme [29].
SP became the first-line anti-malarial drug in Kenya in 1998.
Data from 1999–2000 demonstrated that the Adequate Clinical
and Parasitological Response (ACPR) by day 28 for SP was 54%
among children aged ,5 years in neighbouring Bondo District,
western Kenya [17]. In 2000, the treatment response by day 28 to
amodiaquine (AQ) mono-therapy in symptomatic children ,5
years of age was reported as 89% in Bungoma, western Kenya
[16]. A more recent study conducted in Bondo in 2007, reported
similarly high (90%) ACPR for amodiaquine-artesunate by day 28
[30]. The available data on treatment response to chlorproguanil-
dapsone showed 96% ACPR by day 14, obtained by pooling data
from trials conducted in five African countries in 2000; no data
were available from western Kenya at the start of the study [31].
In 2004, during the course of this trial, the Kenya Ministry of
Health (MOH) adopted artemether-lumefantrine (AL) as the first-
line treatment for uncomplicated malaria [32]; implementation
began in late 2006.
Study Participants
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. Figure S1 depicts the trial time-line for participants.
Inclusion criteria: infants aged 5 to 16 weeks who were resident in
Asembo (study area), when they attended a Mother and Child
Health clinic prior to their first OPV/PENT vaccination at any
one of the 4 study clinics located in 3 large outpatient healthcare
units and 1 mission hospital within the study area were offered
enrolment in the study. Infants were enrolled from within a 3 km
radius of the given health facility as this distance was considered
convenient enough to allow re-visits. Exclusion criteria. Infants
with known allergy to any of the study drugs, receiving
cotrimoxazole prophylaxis for opportunistic infections, suffering
concomitant illness requiring hospitalization or transfusion, or
planning to be away from the study area for more than 6 months
were excluded. The study was explained to parents or guardians of
eligible infants and written informed consent was obtained; see
Consent S1. Comprehension of the consent form was assessed
orally using a standard set of questions. The study was conducted
according to Good Clinical Practice guidelines and monitored by a
Data Safety and Monitoring Board (DSMB). The protocol was
approved by the National Ethical Review Committee of the
Kenya Medical Research Institute (KEMRI) in Nairobi, and the
Institutional Review Board of the Centers for Disease Control and
Prevention in Atlanta, Georgia. The study is registered with
ClinicalTrials.gov (NCT00111163).
Randomization, Allocation Concealment and Blinding
Study arm assignment was done by permuted block random-
ization with a block size of 8. Each study drug combination was
assigned to a colour and then packed into identical bottles labelled
only with the colour, the course number (1, 2, or 3), the day of
treatment (day 1, day 2, or day 3), and whether the drug was drug
A or B of the combination. Labelling was performed by an
independent scientist who was not otherwise involved in this trial.
Doses of study drugs were prepared from these bottles in an
isolated and locked pharmacy room in each study clinic. The list of
study identification numbers linked to a given colour was kept
locked and was accessible solely to the pharmaceutical technician
preparing doses. The colour-arm assignment of the study
identification numbers remained concealed to everyone except
the technician. The technician did not have access to names of
participants. The key to the colour-arm assignment was kept by
the DSMB. The key was obtained in exchange for the locked
dataset and detailed analytical plan.
Study Drug Selection
For the short-acting drug, chlorproguanil-dapsone (CD) was
selected based on demonstrated efficacy in Kenya [31,33–35] and
northern Tanzania [36]. CD has a terminal elimination half-life
(tK) of between 6 and 19 hours [33]. However, since March 2008
CD has no longer been available. The two long-acting anti-
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AQ and SP. Amodiaquine had been shown to be efficacious for
IPTi in neighbouring Tanzania [8], and for treatment in western
Kenya [16]. The desethyl metabolite of AQ, which accounts for
nearly all anti-malarial activity, has a tK of between 3 to 12 days
[37]. Sulphadoxine has a tK of 7 days, whereas pyrimethamine
has a tK of 3 days [38]. Artesunate (AS) was added to both SP and
AQ because of uncertainties of how rising P. falciparum resistance to
SP and AQ alone might compromise efficacy if the primary action
of IPTi was due to parasite clearance. Available data suggest that
AQ plus AS is more efficacious than AQ alone in the treatment
of uncomplicated malaria in symptomatic African children
[39,40]. Similarly, SP plus AS is more efficacious than SP alone
[17,41–43]. Artesunate is very short-acting and has a tK of
approximately 1 hour [18], and was not added to CD because of
the very high treatment success rate observed with CD in Kenya
and northern Tanzania, and because at the time there were no
published studies on the safety or efficacy of a CD plus AS
combination.
Study drug regimens
The study drug regimens were as follows: (i) SP-AS3 (DAFRA
Pharma, Belgium): one SP half-strength tablet (250 mg sulphadox-
ine, 12.5 mg pyrimethamine) once on the first day of treatment
(followed by a placebo SP tablet on days 2 and 3) and one paediatric
artesunate tablet (25 mg) once daily for 3 days; (ii) AQ3-AS3
(DAFRA Pharma, Belgium): one paediatric amodiaquine tablet
(67.5 mg), once daily for 3 days and one paediatric artesunate tablet
(25 mg) once daily for 3 days; (iii) CD3 (GlaxoSmithKline, United
Kingdom): one paediatric caplet (15 mg chlorproguanil and
18.75 mg of dapsone) once daily for 3 days administered with a
placebo once daily for 3 days; and (iv) Placebo (DAFRA Pharma,
Belgium): 2 placebo tablets co-administered once daily for 3 days.
The doses given were the same for all 3 courses of IPTi. All study
drugs were Good Manufacturing Practice certified.
To increase palatability, all medications were dispensed as
crushed tablets mixed with pharmaceutical-grade syrup (Humco
Corporation, Texas, USA) immediately prior to administration in
an opaque syringe. The first dose of each course of study drug was
administered and supervised at the healthcare unit by a study
nurse; subsequent doses of each course were administered and
supervised at home by study staff. All the infants were observed for
30 minutes after drug administration; if vomiting occurred during
that period a repeat dose was administered and supervised at the
healthcare unit by a study nurse. If vomiting occurred during
home administered doses, the child was immediately referred to
the healthcare unit, where a repeat dose was administered.
Supplies of iron sulphate (2 mg/kg/day) (Laboratory and Allied
Ltd., Kenya) were given at the first and second IPTi courses, and 1
month later at the fourth scheduled visit to the parent/guardian of
study children for home administration during a 4-month period
from 2.5 to 6.5 months of age.
Study Procedures
Malaria incidence was estimated through passive surveillance.
Infants with any illnesses were instructed to present to one of the 4
study clinics for care, which was provided free of charge. A rapid
diagnostic test (RDT) (OptiMalH, DiaMed, Switzerland) for
malaria was performed for all infants with a documented fever
($37.5uC by axillary measurement), history of recent fever in the
previous 48 hours, or evidence of pallor. Results of the RDT were
used solely for clinical management and not for trial outcome
measures. If the RDT was positive, the infant was treated with
quinine (7-day course) or AL (for children $12 months of age
weighing .5 kg). If the sick visit and positive RDT occurred at the
10- or 14-week or 9-month visit when study drug was due, then
IPTi and a paired 7-day treatment (prepared for each arm prior to
trial commencement) was given such that the arms containing
active study drugs were paired with placebo, whereas the placebo
arm was paired with quinine. This arrangement ensured that all
participants regardless of study arm received appropriate treat-
ment for clinical malaria. In addition, Hb levels were checked and
blood slides prepared. Any other childhood illnesses were treated
according to the Integrated Management of Childhood Illnesses
and MOH guidelines.
Participants who presented with serious adverse events
suspected to be attributable to study drugs were withdrawn from
receiving further study drugs, but follow-up visits and healthcare
continued. Those who migrated outside the study area for more
than 3 months were suspended from the study but allowed to re-
enter upon returning to the study area, or were considered lost to
follow-up if they failed to return.
Laboratory Methods
Thick blood films prepared from capillary blood were stained
with 10% Giemsa stain (pH 7.2) for 15 minutes and examined for
parasites. Parasites and leukocytes were counted in the same fields
until 500 leukocytes were counted. Due to difficulties in obtaining
sufficient quantities of blood from infants, the logistics of carrying
out complete blood counts in the field or even using accurate
blood volumes (10 mL) to make blood smears, we preferred to use
the WHO recommended method of assumed leukocyte counts in
such areas, also used in some IPTi studies [11,44]. Even though
this method could potentially result in inaccurate estimates of the
parasite densities it would not introduce a bias across study arms.
Parasite densities were estimated using an assumed leukocyte
count of 8,000 leukocytes per mL of blood. All slides were read by
two laboratory technicians independently, who were blinded to
treatment arms. Slides with discrepant readings or with parasite
density estimations that differed by .50% were sent to a senior
technician for a third reading, the result of which was considered
final. All laboratory technicians were trained at the KEMRI and
Walter Reed Project Centre for Excellence in Microscopy in
Kisumu. Capillary blood was collected in micro-cuvettes and
examined in HemocueH photometers (Angelholm, Sweden) to
determine Hb levels. All HemocueH photometers were verified
against known standard micro-cuvettes weekly and sent monthly
for cleaning, maintenance, and verification against a Coulter
CounterH (Beckman Coulter, USA). Capillary blood was also
collected at 12 months of age in tubes containing ethylene diamine
tetra acetic acid (EDTA) for sickle cell status determination using a
standard Hb electrophoresis technique. Samples for glucose-6-
phosphate dehydrogenase genotypes (G6PD) were analysed after
all study subjects had completed the primary follow-up period (12
months) using blood samples collected at enrolment. G6PD
mutations at nucleotides 376 (A – G) and 202 (G – A) were
detected by polymerase chain reaction followed by digestion with
restriction endonucleases FokI and NlaIII respectively [45].
Outcomes
The primary outcome was time to the first or only episode of
clinical malaria in the first year of life. An episode of clinical
malaria was defined as an axillary temperature of at least 37.5uC
or history of fever in the preceding 48 hours together with asexual
P. falciparum parasitaemia of any density. Percent of febrile episodes
attributable to malaria, cut-off parasite densities, and sensitivity
and specificity of the cut-off densities for this site have been
described elsewhere [46].
IPTi Malaria Prevention Kenya
PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e10016Secondary outcomes (time to event) were; moderate-to-severe
anaemia (defined as Hb ,8 g/dL) and all-cause hospitalizations in
the first year of life, as defined in the protocol. In addition, other
secondary outcomes included high density clinical malaria (defined
as clinical malaria with parasite densities .5,000/mL of blood [time
to event]); mild anaemia (defined as Hb ,11 g/dL [time to event]);
multiple episodes of clinical malaria (number of events over follow-
up time); all-cause outpatient sick visits (time to event); hospitaliza-
tions with malaria (time to event); and the incidence of clinical
malaria was also assessed to determine the duration of effect
(number of events over follow-up time) and any rebound effect in
the second year of life (e.g. increase in malaria incidence following
discontinuation of IPTi). All additional outcomes were pre-specified
before analysis; some were included in a separate analysis plan
because we felt they were clinically important indicators, whereas
others were included in order to facilitate comparability with other
IPTi studies. The analysis plan was drawn up after the protocol was
written (before analysis) to be comparable to other IPTi trials; see
Analysis Plan S1 and Protocol S1.
Sample Size
Preliminary sample size calculations were conducted for the
outcome time to first episode of clinical malaria in the first 18
months of age and were based on the log-rank test. Median time in
the placebo group receiving iron was assumed to be 18 months
(168 weeks after the first intervention visit) [28]. The sample size
required for 90% power to detect a hazard ratio of 0.6 (protective
efficacy [PE] OF 40%, PE defined as [1- hazard ratio] 6100%)
assuming alpha =0.017 to correct for three pair wise comparisons
was 1000 infants (250 per arm). Adjusting for 10% loss to follow-
up, 13% mortality and 11% of infants contracting malaria before
the first treatment regimen resulted in a sample size of 1,516
infants (379 per arm).
Data Management and Statistical Methods
Data were entered using scan-ready TeleformsH and an optical
scanner (Cardiff, California, USA). Data were checked for internal
consistency and out-of-range values. Study subjects were enrolled
4 weeks prior to receiving the first intervention, and were
subsequently excluded from analysis if diagnosed with clinical
malaria or they died or out-migrated from the study area within
that 4-week period. This modified ITT population included all the
participants who received the first course of study drug regardless
of whether they received all or part of the interventions. We used
Cox regression models to estimate the risk of the first or only
episode of clinical malaria during the period starting from the first
intervention visit and ending at 1 year of age or at censoring due to
withdrawal or death [47]. The models’ assumption regarding the
proportionality of the hazard ratio was analyzed by assessing the
interaction between age and effect of treatment with a time-
dependent Cox regression model. Kaplan-Meier curves were used
to plot the time to event analyses. Secondary analyses were
performed to assess the effect of non-compliance on the efficacy
estimates derived from the primary analysis. Only those who had
received all three doses of IPTi or placebo within 28 days of the
scheduled intervention visits were included in these per-protocol
analyses. Multiple malaria episodes and hospital admissions were
assessed using Generalised Estimating Equations (GEE) Poisson
regression models to take into account intra-individual correlation
[48]. During the 28 days following treatment for an episode of
clinical malaria, participants were considered not at risk for a new
episode of malaria, and any positive blood smear during that time
period was considered a recrudescence. Furthermore, if a subject
migrated outside the study area for 3 or more consecutive months
at any given time and returned prior to the end of the trial, it
would be reported by a Compliance Monitor, and they would be
included in the multiple episodes analysis but considered not at
risk for the period of their absences.
Post-dose analyses were done: firstly, by fixing a Cox regression
model to look at the primary endpoint within a 30day period after
each course of IPTi; and secondly, by using biweekly time versus
treatment interaction models excluding the first IPTi course
because the period of post-treatment prophylaxis overlapped with
the second IPTi course of treatment. A Lexis expansion [49] was
used to obtain estimates within defined time strata at 14 day
intervals after IPTi courses 2 and 3 by fitting a Poisson regression
model with time versus treatment interaction, and using GEE to
take into account intra-individual correlation. Multiple episodes of
clinical malaria were assessed, and PEs calculated within each
consecutive period of 14 days after each of the relevant courses of
IPTi. Infants were excluded from the analysis for a period of 28
days after each event. The Poisson model was pooled across the
respective IPTi courses allowing for a more robust estimation of
PEs over time. Biweekly intervals were preferred for analysis
because some weekly intervals had very few episodes of clinical
malaria or lacked them altogether. Anthropometric indices were
calculated using growth references from the National Center for
Health Services, USA and the World Health Organization [50].
The analysis was performed using SAS version 9.1.3 (SAS
Institute, Cary, North Carolina, USA), and STATA version 10
(STATA Corporation, College Station, Texas, USA).
Results
Participant and Baseline Characteristics
Between March 2004 and March 2008, 1,365 (90.0%) of 1,516
randomized infants received $1 dose of study drug and were
included in the ITT analysis. Fifty-five (4.0%) out of the 1,365
died, 38 (2.8%) withdrew consent, and 191 (14.0%) were lost to
follow-up due to migration; 1,081 (79.2%) completed the 1-year
follow-up period (Figure S2). The four study groups were
comparable with regard to sex, Hb genotype, G6PD phenotype,
weight-for-age, age at first, second, and third IPTi courses, use of
ITNs, and compliance with iron supplementation during the first
year of life (table 1).
Protective Efficacy (PE) against main Outcomes
The incidence of clinical malaria between the first dose of IPTi
and 12 months of age was 0.98 episodes per person-year in the
placebo group and 0.74, 0.76, and 0.82 in the SP-AS3, AQ3-AS3,
and CD3 groups, respectively. The PE against the first or only
episode of clinical malaria was 25.7% (95% CI: 6.3, 41.1;
p=0.012) in the SP-AS3 group and 25.9% (95% CI: 6.8, 41.0;
p=0.01) in the AQ3-AS3 group, when compared with placebo.
When multiple episodes of clinical malaria were considered the
results were similar: 22.2% (95% CI: 2.5, 37.8; p=0.029) and
24.7% (95% CI: 6.4, 39.5; p=0.011), in the SP-AS3 and AQ3-
AS3 groups, respectively. Narrowing the case definition for clinical
malaria to those with .5,000 parasites (par)/ mL of blood yielded
a PE against the first or only episode of 48.9% (95% CI: 12.2,
70.3; p=0.015) in the SP-AS3 group. The PE against the first or
only episode of mild anaemia (Hb ,11.0 g/dL) was 20.3% (95%
CI: 4.0, 33.9; p=0.017) in the AQ3-AS3 group; details are shown
in table 2. Kaplan-Meier survival plots of the observed data are
shown in Figure S3. CD3 did not provide a significant PE for any
of the outcomes measured. None of the IPTi regimens appeared to
provide statistically significant protection against all-cause outpa-
tient sick visits, hospitalizations with malaria, or all-cause
IPTi Malaria Prevention Kenya
PLoS ONE | www.plosone.org 4 April 2010 | Volume 5 | Issue 4 | e10016hospitalizations (table 2). There was no evidence that the
assumption of proportional hazards was violated when we assessed
the interaction between age and treatment in the time-dependent
Cox model, and comparison of the crude and adjusted models
suggested adjustment for co-variates was not required as inclusion
of co-variates did not affect the point estimate or its precision.
Post-dose Efficacy against Malaria
The PE against the first or only episode of clinical malaria
within a period of 30 days after the 1
st course of IPTi was 88.7%
(95% CI: 50.9, 97.4; p=0.004) in the SP-AS3 group, 66.6% (95%
CI: 15.2, 86.8; p=0.021) in the AQ3-AS3 group, and 66.1% (95%
CI: 14.0, 86.6; p=0.023) in the CD3 group. The corresponding
figures after the 2
nd course of IPTi were 86.6% (95% CI: 61.8,
95.3; p,0.001), 73.1% (95% CI: 40.9, 87.7; p=0.001), and 61.8%
(95% CI: 23.3, 81.0; p=0.007) in the SP-AS3, AQ3-AS3 and
CD3 groups, respectively. By contrast, the corresponding PEs after
the 3
rd course of IPTi were far lower and not statistically
significant (table 3).
The pooled post-dose analysis using biweekly time versus
treatment interaction models showed that the duration of
protective efficacy was longest (5 to 8 weeks) for the combinations
based on sulphadoxine-pyrimethamine and amodiaquine reflect-
ing their longer half-lives compared to CD3. It also showed that
the protective effect declined rapidly thereafter and was no longer
evident beyond 8 weeks (Figure S4).
Per-protocol Analyses
The per-protocol analyses provided similar estimates, and none
of the outcomes (PEs) differed by more than 15% as compared to
ITT analyses. Therefore, only the ITT analyses are presented.
Tolerability
Those taking study drugs were more likely to vomit than those
taking placebo, prevalence ratios 1.77 (95% CI: 1.14, 2.74; p=0.010),
2.15 (95% CI: 1.41, 3.28; p,0.001), and 2.36 (95% CI: 1.55, 3.59;
p,0.001) in the SP-AS3, AQ3-AS3, and CD3 groups, respectively.
Out of 11,568 drug doses administered, only 2.1% were vomited.
Safety and Morbidity
There were 593 serious adverse events (SAEs) recorded during
the 1
st year of life. Of these SAEs, 55 were deaths and 538 were
hospitalizations. Although, the number of deaths was highest in
the CD3 group, their difference was not statistically significant.
The one death classified as possibly related in the CD3 arm was
the case of a 3 month old female infant born on 27th August 2005
and enrolled into the study on 3rd October 2005. First dose of
IPTi study drug was administered from 31st October to 2nd
November 2005 and the second dose from 28th to 30th November
2005. She was well when both the first and second doses of IPTi
were administered. She left the study area with the mother for
their rural home on 1st December 2005 when she fell ill with
vomiting of feeds and diarrhoea. The stool was watery, copious in
amount and frequent. There was no history of fever, convulsions
or cough. No treatment was sought on that day. The following
day, she became restless and developed fast breathing, and again
no treatment was sought. She passed away on 3rd December
2005, the third day of illness at home.
There was no significant difference in the number of SAEs in the
SP-AS3, AQ3-AS3, and CD3 groups as compared to placebo.
Fifteen were assessed as possibly related to study drug, 6 in the SP-
AS3 group, 5 in the AQ3-AS3 group, and 4 in the CD3 group
(table4).The SAEsclassified as possiblyrelated were hospitalizations
due to expected childhood illnesses which occurred within one
month of administering IPTi, and further evaluation showed that
none of the SAEs were directly related to any of the administered
study drugs.Noserious cutaneousadverseeventswere noted,and no
cases of severe haemolysis were recorded. Male study participants in
the CD3 arm (n=251) with G6PD deficiency were more likely than
those without G6PD deficiency to have moderate-to-severe anaemia
Table 1. Characteristics of IPTi study groups in western Kenya.
Parameter Placebo SP-AS3 AQ3-AS3 CD3
(n=337) (n=339) (n=347) (n=342)
Male sex [%] 46.9 53.1 53.9 50.6
Hb genotype{:
AA [%] 75.3 76.1 78.4 76.7
AS 0 23.3 22.9 18.9 21.0
SS 0 0.4 0.4 0.7 0.4
Other 0 1.1 0.7 2.1 2.0
G6PD deficiency:
Normal [%] 73.9 71.6 68.0 72.2
Mild-deficient 0 12.5 15.4 13.3 11.4
Deficient 0 13.6 13.0 18.7 16.4
Age [months]-1
st IPTi (mean6sd) 2.760.4 2.760.4 2.760.5 2.760.5
Age [months]-2
nd IPTi 0 3.760.5 3.760.5 3.760.6 3.760.6
Age [months]-3
rd IPTi 0 9.260.3 9.260.3 9.260.3 9.260.3
Weight-for-age z score – 1
st IPTi 0 0.361.1 0.361.1 0.361.1 0.361.1
ITN use-night before 1
st IPTi [%] 77.7 76.6 75.6 74.0
,67% iron compliance*[%] 16.0 16.7 17.9 15.8
Note: *at the end of iron supplementation (6.5 months of age), compliance measured as percentage of iron taken over the expected; {at 1 year of age; [%] figure is
presented as a percentage.
doi:10.1371/journal.pone.0010016.t001
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PE -166.8% (95% CI: 2497.5, 219.1; p,0.017).
Rebound Analyses
The period under observation for the ‘rebound analyses’ started
from 30 days after the 3
rd course of IPTi (10 months of age) until
24 months of age, and all participants who received at least one
dose of study drug and were still being followed-up during that
period were included in the analyses (table 5). There was no
statistically significant rebound for the first or only episode of
clinical malaria, multiple episodes of clinical malaria, mild
anaemia, and moderate-to-severe anaemia. For a more specific
definition of clinical malaria (.5,000 par/mL of blood), statisti-
Table 2. Incidence of the main outcomes during the first year of life.
Outcomes Placebo SP-AS3 AQ3-AS3 CD3
1
st or only cl mal (n=337) (n=339) (n=347) (n=342)
Events/PYAR 158/161.0 130/176.3 137/181.4 136/166.2
Rate 0.98 0.74 0.76 0.82
PE % (95% CI) Reference: 25.7 (6.3, 41.1) 25.9 (6.8, 41.0) 16.3 (-5.2, 33.5)
p-Value 0.029 0.011 0.324
All episodes cl mal (n=337) (n=339) (n=347) (n=342)
Events/PYAR 263/197.0 209/201.1 213/212.0 233/195.0
Rate 1.33 1.04 1.00 1.20
PE % (95% CI) Reference: 22.2 (2.5, 37.8) 24.7 (6.4, 39.5) 10.5 (–11.6, 28.2)
p-Value 0.029 0.011 0.324
Cl mal (.5,000par/mL) (n=346) (n=350) (n=354) (n=347)
Events/PYAR 38/206.3 20/213.1 25/219.8 36/203.0
Rate 0.18 0.09 0.11 0.18
PE % (95% CI) Reference: 48.9 (12.2, 70.3) 41.2 (2.5, 64.5) 3.4 (252.3, 38.8)
p-Value 0.015 0.040 0.880
Anaemia (Hb,11 g/dL) (n=321) (n=335) (n=324) (n=326)
Events/PYAR 232/114.8 221/128.9 214/127.3 223/118.5
Rate 2.02 1.71 1.68 1.88
PE % (95% CI) Reference: 16.4 (20.6, 30.4) 20.3 (4.0, 33.9) 8.0 (210.6, 23.5)
p-Value 0.057 0.017 0.375
Anaemia (Hb,8 g/dL) (n=350) (n=355) (n=357) (n=351)
Events/PYAR 59/199.3 45/209.5 51/213.4 52/198.7
Rate 0.30 0.21 0.24 0.26
PE % (95% CI) Reference: 27.5 (26.9, 50.8) 23.1 (211.9, 47.2) 11.4 (228.6, 39.0)
p-Value 0.105 0.170 0.525
Out-patient visits (n=337) (n=339) (n=347) (n=342)
Events/PYAR 1996/210.7 1947/211.1 2125/221.5 2051/206.6
Rate 9.47 9.22 9.59 9.93
PE % (95% CI) Reference: 2.6 (24.9, 9.7) 21.3 (29.4, 6.2) 24.8 (213.2, 2.9)
p-Value 0.482 0.746 0.229
All hospitalizations (n=337) (n=339) (n=347) (n=342)
Events/PYAR 137/210.9 127/211.4 147/221.7 130/206.9
Rate 0.65 0.60 0.66 0.63
PE % (95% CI) Reference: 7.5 (219.7, 28.5) 22.1 (232.1, 21.1) 3.3 (228.6, 27.3)
p-Value 0.553 0.875 0.818
Hospitalizations with:
Clinical malaria (n=337) (n=339) (n=347) (n=342)
Events/PYAR 57/210.9 61/211.4 67/221.7 58/206.9
Rate 0.27 0.29 0.30 0.28
PE % (95% CI) Reference: 26.8 (261.5, 29.4) 211.8 (267.9, 25.5) 23.7 (260.6, 33.0)
p-Value 0.756 0.590 0.871
Cl mal = clinical malaria; PYAR = person-years-at-risk; PE = protective efficacy; CI = confidence interval. All episodes (GEE Poisson model); other outcomes (Cox
model).
doi:10.1371/journal.pone.0010016.t002
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263.0% (95% CI: 2142.5, 210.5; p=0.014) (table 5).
Discussion
Our results indicate that two long-acting combinations (SP-AS3
and AQ3-AS3), but not a short-acting combination (CD3)
provided significant protection against the first or only episode
of clinical malaria and anaemia in this area with year round
malaria transmission with high seasonal intensity, near universal
usage of ITNs, and a high level of P. falciparum resistance to SP.
The SP-AS3 and AQ3-AS3 groups also provided much higher
protection against the first or only episode of high density clinical
malaria. These results suggest that the prophylactic effect is more
important for the mode of action of IPTi. It is reassuring to note
that protective efficacy against multiple episodes of clinical malaria
was fairly similar to the primary endpoint, as the multiple episodes
endpoint has more direct relevance to public health interpretation.
The PE of 26% against clinical malaria provided by SP-AS3 is
similar to that reported in earlier IPTi trials with SP alone [9–12]
with the exception of the initial Tanzanian study which reduced
clinical malaria by 59% [7]. Our results also suggest that AQ may
be a suitable alternative to SP for IPTi. However, our results with
AQ3-AS3 (PE 23% against clinical malaria) were less dramatic
than the 65% protection reported using AQ alone in Tanzania.
[8]. The Tanzanian trial of AQ was quite different in that IPTi
administration was not linked to EPI and the 3 doses were given
60 days apart, beginning at 12–16 weeks of age. We found that
AQ3-AS3 was tolerated as well as the other IPTi drug
combinations used in this trial. Although the acceptance of AQ
is sometimes poor among adults and pregnant women being
treated for clinical malaria [51–54], data from our blinded trial
does not suggest that tolerability is a problem in infants.
In contrast to the earlier study in Tanzania [19], our trial did
not show a sustained benefit of IPTi in the second year of life. It is
not clear why that initial trial showed a much higher protection in
the first year of life and observed persistence of protection in the
second year of life, whereas subsequent trials have not [55]. A
comparative analysis of the Tanzanian trial and another IPTi trial
in Mozambique suggested that the high ITN coverage in
Tanzania at the time of the trial was likely responsible for the
dramatically higher efficacy there [56]. The results of our trial, in
which ITN ownership and usage was very high, do not lend
support to that hypothesis. The observed difference in the second
year could be explained by a decrease in malaria transmission in
the Tanzanian study during the study period, as recently suggested
by Gosling et al. [55]. It may also be that the results were at the
higher end of the normal variation of protective efficacy, with
subsequent trials showing regression toward the mean. While there
Table 3. Incidences of the primary outcome 30 days after each course of IPTi.
Outcomes Placebo SP-AS3 AQ3-AS3 CD3
Cl mal after IPTi-1 (n=337) (n=339) (n=347) (n=342)
Events/PYAR 17/27.1 2/27.8 6/28.3 6/27.9
Rate 0.63 0.07 0.21 0.22
PE % (95% CI) Reference: 88.7 (50.9, 97.4) 66.6 (15.2, 86.8) 66.1 (14.0, 86.6)
p-Value 0.004 0.021 0.023
Cl mal after IPTi-2 (n=320) (n=323) (n=322) (n=315)
Events/PYAR 28/25.2 4/26.4 8/26.3 11/25.6
Rate 1.11 0.15 0.30 0.43
PE % (95% CI) Reference: 86.6 (61.8, 95.3) 73.1 (40.9, 87.7) 61.8 (23.3, 81.0)
p-Value ,0.001 0.001 0.007
Cl mal after IPTi-3 (n=268) (n=273) (n=288) (n=246)
Events/PYAR 23/20.9 15/21.9 17/23.0 18/19.8
Rate 1.10 0.68 0.74 0.91
PE % (95% CI) Reference: 38.1 (218.7, 67.7) 33.4 (224.7, 64.4) 17.5 (252.9, 55.5)
p-Value 0.149 0.205 0.542
Cl mal = clinical malaria; PYAR = person-years-at-risk; PE = protective efficacy; CI = confidence interval. All outcomes (Cox model).
doi:10.1371/journal.pone.0010016.t003
Table 4. Summary of Serious Adverse Events (SAEs) during
the first year of life.
Type of AE Placebo SP-AS3 AQ3-AS3 CD3
SAEs (n=337) (n=339) (n=347) (n=342)
Deaths
Not related 9 9 14 15
Unlikely 3 1 1 2
Possibly related – – – 1
Total 12 10 15 18
Hospitalizations 135 128 147 128
All SAEs
Events/PYAR 147/1533.8 138/1530.3 162/1683.9 146/1549.8
Rates 0.10 0.09 0.10 0.09
RR (95% CI) Reference: 0.94
(0.74, 1.27)
1.00
(0.79, 1.27)
0.98
(0.75, 1.27)
p-Value 0.617 0.975 0.896
Possibly related 5 6 5 4
RR = Relative risk; PYAR = person-years-at-risk; outcome (Poisson model).
doi:10.1371/journal.pone.0010016.t004
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lower than in later infancy in many settings, the results of this and
other trials suggest that there is a significant protective efficacy
after the first dose of IPTi. Therefore, while the EPI schedule may
not provide the optimal spacing (especially the gap between 14
weeks and 9 months), it does provide a readily usable delivery
platform. Furthermore, earlier randomised controlled trials with
ITNs in the same study site showed that most of the benefit of
ITNs occurred in the first 6 months of life and that this became
apparent from 2 months of age onwards [57].
Similar to the previous trials with SP alone, we also observed a
high PE with SP-AS3 in the 30 days after the first two courses of
IPTi suggesting that the impact of rising resistance of P. falciparum
to SP as evidenced by decreased efficacy in the treatment of
symptomatic children with malaria may not be as dramatic when
SP is used for IPTi in early infancy. It may be that the presence of
maternal antibodies and foetal haemoglobin during the first two
courses of IPTi result in lower parasite densities in asymptomatic
children and therefore in better clearance, even with imperfect or
even failing anti-malarial drugs. Given the short terminal half-life
of AS, and our data suggesting that the prophylactic rather than
the treatment effect of IPTi is central to its protective efficacy, it is
unlikely that the addition of AS to SP had a substantial impact on
its PE as IPTi; without an SP-alone arm, it is not possible to
confirm this hypothesis. The reason behind our observed
reduction in PEs, which occurs after the 5-month interval between
the second and third courses of IPTi, is not clear. It may be the
result of a complex interplay of factors including the loss of
maternal antibodies, the development of naturally acquired
immunity by all children (including the healthy survivors in the
placebo group, thereby diminishing any differences between those
in the intervention and placebo arms), limited exposure to malaria
parasites (due to protection by high usage of ITNs), and even
though a certain amount of relative under dosing may have
occurred due to natural weight-gain with age, any effects of
relative under dosing would likely have been randomly distributed
across the study arms.
A closer look at the results of the post-dose analysis using
biweekly time interaction models shows that the post-treatment
prophylactic effect does not extend beyond 5 to 8 weeks after
receiving SP-AS3 or AQ3-AS3. The results are very similar to a
more detailed analysis of the duration of protection against clinical
malaria provided by Cairns et al on the data from Navrongo.
These also found that the duration of protective efficacy was short-
lived and lasted for 4 to 6 weeks only, reflecting the prophylactic
effect of IPTi (the duration varied with the endpoint used in the
analysis). Similar to our study, there was no evidence for a
sustained effect thereafter [20].
Table 5. Incidences of main outcomes between 10 to 24 months of age follow-up.
Outcomes Placebo SP-AS3 AQ3-AS3 CD3
1
st or only cl mal (n=282) (n=285) (n=296) (n=262)
Events/PYAR 151/200.2 157/211.4 162/210.1 147/179.1
Rate 0.75 0.74 0.77 0.82
PE % (95% CI) Reference: 1.5 (223.1, 21.2) 21.1 (226.3, 19.0) 27.3 (234.6, 14.5)
p-Value 0.892 0.92 0.544
All episodes cl mal (n=283) (n=286) (n=297) (n=262)
Events/PYAR 456/284.0 464/292.9 475/297.4 480/256.7
Rate 1.61 1.58 1.60 1.87
PE % (95% CI) Reference: 1.3 (219.8, 18.7) 1.0 (220.8, 18.1) 216.5 (241.2, 3.9)
p-Value 0.892 0.957 0.120
Cl mal (.5,000 par/mL) (n=283) (n=286) (n=297) (n=262)
Events/PYAR 42/288.7 47/298.0 51/300.3 61/255.2
Rate 0.15 0.16 0.17 0.24
PE % (95% CI) Reference: 28.6 (264.6, 28.4) 216.7 (275.6, 22.4) 263.7 (2142.5, 210.5)
p-Value 0.699 0.458 0.014
Anaemia (Hb,11 g/dL) (n=279) (n=281) (n=295) (n=260)
Events/PYAR 239/96.7 238/105.5 254/107.3 211/93.7
Rate 2.47 2.26 2.37 2.25
PE % (95% CI) Reference: 8.2 (29.8, 23.3) 3.3 (215.4, 19.0) 6.5 (212.5, 22.3)
p-Value 0.349 0.707 0.478
Anaemia (Hb,8 g/dL) (n=282) (n=285) (n=298) (n=261)
Events/PYAR 66/257.5 53/268.9 62/274.2 57/243.6
Rate 0.26 0.20 0.23 0.23
PE % (95% CI) Reference: 22.2 (211.7, 45.8) 11.2 (225.6, 37.2) 8.0 (231.1, 35.5)
p-Value 0.173 0.502 0.643
Cl mal = clinical malaria; PYAR = person-years-at-risk; PE = protective efficacy; CI = confidence interval. All episodes (GEE Poisson model); other outcomes (Cox
model).
doi:10.1371/journal.pone.0010016.t005
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AQ- containing combinations in the second year of life, suggesting
that IPTi does not have a negative impact on the development of
immunity to malaria. However, compared to the placebo arm, a
higher rate of clinical malaria (.5,000 par/mL of blood) was noted
in the CD3 group. It is possible that this may have been a chance
finding, given the absence of a similar rebound effect with any of
the other clinical endpoints, and considering the unlikely influence
of CD3 on the acquisition of natural immunity due to its relatively
short terminal half-life.
Some limitations to our study should be noted. First, SP and AQ
were used in combination with AS, but this study was not designed
to address the contribution of the rapidly eliminated artemisinin
derivatives, and their contribution to the effect of IPTi still remains
unclear. Any direct benefit would have resulted in the improved
radical cure of existing infections over and above that of SP or AQ
mono-therapy. The benefit would be greatest to infants with
higher density parasitaemias, as low density infections would more
likely have been cleared successfully even in the presence of mild
to moderate resistant infections [58]. Thus one of the main
benefits of adding an artemisinin derivative is probably the
prevention of abuse of mono-therapies by reducing chances of the
further development of resistance in the population [18].
However, this needs to be weighed against the risk of decreased
adherence if combination therapy for IPTi results in longer and
more complex regimens (e.g. single dose SP versus 3 days of SP-
AS3). Thus our results obtained with these multi-day regimens in
this trial should be interpreted with some caution as all doses were
administered under direct supervision, which clearly would not be
feasible for programmatic use.
Second, the high usage of ITNs may potentially provide
competing or added benefits in reducing clinical malaria and
anaemia. The effect of ITNs as a potential effect modifier could
not be assessed in our study because ITNs were provided to all
participants at enrolment. This was done because the benefits of
using ITNs had already been conclusively demonstrated in the
same study area [25], and there was already a very high rate of
ownership and usage in the community. Third, we facilitated
hospitalization–generally at the Provincial Hospital–for all partic-
ipants. Our conservative approach to hospitalization may have
resulted in a dilution of any effect of IPTi on hospitalization rates.
Fourth, preliminary sample size calculations were based on
assumptions of 90% power and 40% efficacy similar to the initial
Tanzanian trial [7]. Though, the PE for our trial was much lower
(similar to more recent IPTi trials), we were still able to achieve
statistical significance because our assumption of a median time to
first episode of clinical malaria was overly conservative, along with
our relatively high estimates of loss to follow-up and mortality.
Fifth, our trial was not designed to investigate mortality, though
the pooled analysis suggests that IPTi does not reduce mortality
when compared with placebo [59].
Conclusion
In conclusion, our results support the view that long-acting but
not short-acting regimens are suitable for IPTi in areas of year
round malaria transmission with high seasonal intensity and high
ITN coverage, and that the prophylactic rather than the
treatment effect of IPTi appears central to its protective efficacy.
The results of this study are relevant for other IPT strategies such
as IPT in pregnancy (IPTp) and IPT in children (IPTc), and
contribute to the development of target product profiles for
alternative drugs to be used for IPT. There is need to confirm
these results in other settings, to investigate the potential gap
between efficacy and effectiveness for multi-day regimens, and to
test other long-acting combinations such as dihydroartemisinin-
piperaquine.
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